Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1776-260X
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) ; volume:16 ; number:5 ; day:3 ; month:9 ; year:2021 ; pages:613-623 ; date:9.2021
Targeted oncology ; 16, Heft 5 (3.9.2021), 613-623, 9.2021

Classification
Medizin, Gesundheit

Creator
Evans, Rachel
Hawkins, Neil
Dequen-O’Byrne, Pascale
McCrea, Charles
Muston, Dominic
Gresty, Christopher
Ghate, Sameer R.
Fan, Lin
Hettle, Robert
Abrams, Keith R.
Bono, Johann de
Hussain, Maha
Agarwal, Neeraj
Contributor
SpringerLink (Online service)

DOI
10.1007/s11523-021-00837-y
URN
urn:nbn:de:101:1-2021121907174022632146
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Evans, Rachel
  • Hawkins, Neil
  • Dequen-O’Byrne, Pascale
  • McCrea, Charles
  • Muston, Dominic
  • Gresty, Christopher
  • Ghate, Sameer R.
  • Fan, Lin
  • Hettle, Robert
  • Abrams, Keith R.
  • Bono, Johann de
  • Hussain, Maha
  • Agarwal, Neeraj
  • SpringerLink (Online service)

Other Objects (12)

Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina

Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Targeting molecular resistance in castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Osteoclasts directly influence castration-resistant prostate cancer cells

Osteoclasts directly influence castration-resistant prostate cancer cells

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Effect of simvastatin on castration-resistant prostate cancer cells

Effect of simvastatin on castration-resistant prostate cancer cells

Ureter metastatic castration-resistant prostate cancer: a case report

Ureter metastatic castration-resistant prostate cancer: a case report

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Chromogranin A: a useful biomarker in castration-resistant prostate cancer

Chromogranin A: a useful biomarker in castration-resistant prostate cancer

Ailanthone: a new potential drug for castration-resistant prostate cancer

Ailanthone: a new potential drug for castration-resistant prostate cancer

Related objects